Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent signaling

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 287, Issue 3 56-3, 2004, Pages

  Ritchie, Rebecca H ^a,b   Rosenkranz, A C ^a   Huynh, L P ^a   Stephenson, T ^b   Kaye, D M ^b   Dusting, G J ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Cardiac hypertrophy; Endothelin 1; Prostacyclin; Protein synthesis

Indexed keywords

6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; ANGIOTENSIN; CICAPROST; CYCLIC AMP; ENDOTHELIN 1; ILOPROST; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PHENYLALANINE; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROSTANOID RECEPTOR; PROTEIN C FOS;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; ONCOGENE C FOS; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II; ANIMALS; BIOLOGICAL MARKERS; CARDIOMEGALY; CYCLIC AMP; ENDOTHELIN-1; EPOPROSTENOL; ILOPROST; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION;

EID: 4143096936     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00725.2003     Document Type: Article

References (35)

1. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T, and Komuro I. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105: 1240-1246, 2002.
2. Belvisi MG, Saunders M, Yacoub M, and Mitchell JA. Expression of cyclo-oxygenase-2 in human airway smooth muscle is associated with profound reductions in cell growth. Br J Pharmacol 125: 1102-1108, 1998.
3. Coleman RA, Smith WL, and Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46: 205-229, 1994.
4. Binchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, Gorry SA, and Trzaskos JM. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378: 406-409, 1995.
5. Dusting GJ and Macdonald PS. Prostacyclin and vascular function: implications for hypertension and atherosclerosis. Pharmacol Ther 48: 323-344, 1990.
6. Force T, Pombo CM, Avruch JA, Bonventre JV, and Kyriakis JM. Stress-activated protein kinases in cardiovascular disease. Circ Res 78: 947-953, 1996.
7. Forman BM, Chen J, and Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94: 4312-4317, 1997.
8. Fujino T, Yuhki K, Yamada T, Kara A, Takahata O, Okada Y, Xiao CY, Ma H, Karibe H, Iwashima Y, Fukuzawa J, Hasebe N, Kikuchi K, Narumiya S, and Ushikubi F. Effects of the prostanoids on the proliferation or hypertrophy of cultured murine aortic smooth muscle cells. Br J Pharmacol 136: 530-539, 2002.
9. Gohlke P, Kuwer I, Bartenbach S, Schnell A, and Unger T. Effect of low-dose treatment with perindopril on cardiac function in stroke-prone spontaneously hypertensive rats: role of bradykinin. J Cardiovasc Pharmacol 24: 462-469, 1994.
10. Hefti MA, Harder BA, Eppenberger HM, and Schaub MC. Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol 29: 2873-2892, 1997.
11. Hoshikawa Y, Voelkel NF, Gesell TL, Moore MD, Morris KG, Alger LA, Narumiya S, and Geraci MW. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med 164: 314-318, 2001.
12. Jones RL, Qian YM, Wise H, Wong HN, Lam WL, Chan HW, Yim AP, and Ho JK. Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery. J Cardiovasc Pharmacol 29: 525-535, 1997.
13. Kapiloff MS. Contributions of protein kinase A anchoring proteins to compartmentation of cAMP signaling in the heart. Mol Pharmacol 62: 193-199, 2002.
14. Lefer AM, Ogletree ML, Smith JB, Silver MJ, Nicolaou KC, Barnette WE, and Gasic GP. Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science 200: 52-54, 1978.
15. Leinwand LA. Calcineurin inhibition and cardiac hypertrophy: a matter of balance. Proc Natl Acad Sci USA 98: 2947-2949, 2001.
16. Linz W and Scholkens BA. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 20, Suppl 9: S83-S90, 1992.
17. Lorell BH and Carabello BA. Left ventricular hypertrophy-pathogenesis, detection, and prognosis. Circulation 102: 470-479, 2000.
18. Moncada S, Gryglewski R, Bunting S, and Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663-665, 1976.
19. Nagaya N, Yokoyama C, Kyotani S, Shimonishi M, Morishita R, Uematsu M, Nishikimi T, Nakanishi N, Ogihara T, Yamagishi M, Miyatake K, Kaneda Y, and Tanabe T. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation 102: 2005-2010, 2000.
20. Nakagawa O, Tanaka I, Usui T, Harada M, Sasaki Y, Itoh H, Yoshimasa T, Namba T, Narumiya S, and Nakao K. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 90: 1643-1647, 1994.
21. Namba T, Oida H, Sugimoto Y, Kakizuka A, Negishi M, Ichikawa A, and Narumiya S. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J Biol Chem 269: 9986-9992, 1994.
22. 2-receptors and molecular mechanisms in platelets and vasculature: state of the art. Pharmacol Res Commun 19: 735-765, 1987.
23. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, and Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349: 747-752, 1997.
24. Ritchie RH, Marsh JD, Lancaster WD, Diglio CA, and Schiebinger RJ. Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells. Hypertension 31: 39-44, 1998.
25. Ritchie RH, Schiebinger RJ, Lapointe MC, and Marsh JD. Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Am J Physiol Heart Circ Physiol 275: H1370-H1374, 1998.
26. Rosenkranz AC, Hood SG, Woods RL, Dusting GJ, and Ritchie RH. Acute antihypertrophic actions of bradykinin in the rat heart: importance of cyclic GMP. Hypertension 40: 498-503, 2002.
27. Rosenkranz AC, Woods RL, Dusting GJ, and Ritchie RH. Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc Res 57: 515-522, 2003.
28. 2 in vitro. Naunyn Schmiedebergs Arch Pharmacol 316: 252-255, 1981.
29. Shirotani M, Yui Y, Hattori R, and Kawai C. U-61,431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells. Prostaglandins 41: 7-110, 1991.
30. Sitbon O, Humbert M, and Simonneau G. Primary pulmonary hypertension: current therapy. Prog Cardiovasc Dis 45: 115-128, 2002.
31. 2 analogue, cicaprost (ZK 96480), in different animal species and in man. Biomed Biochim Acta 47: S45-S47, 1998.
32. 2-prostacyclin regulatory system. Biochim Biophys Acta 31: 1-2, 2001.
33. Vane JR and Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol 75: 3A-10A, 1995.
34. Yokoyama C, Yabuki T, Shimonishi M, Wada M, Hatae T, Ohkawara S, Takeda J, Kinoshita T, Okabe M, and Tanabe T. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 106: 2397-2403, 2002.
35. Yu H, Gallagher AM, Garfin PM, and Printz MP. Prostacyclin release by rat cardiac fibroblasts: inhibition of collagen expression. Hypertension 30: 1047-1053, 1997.